FDA Fast-Tracks LBS-007 for Acute Myeloid Leukemia
Acute Myeloid Leukemia (AML) is a relentless blood cancer that demands aggressive treatment. For patients with relapsed or resistant AML, the options have been limited. However, there’s a glimmer of hope on the horizon. The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to LBS-007, a novel therapy with the potential to […]
FDA Fast-Tracks LBS-007 for Acute Myeloid Leukemia Read More »